- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 231/18 - One oxygen or sulfur atom
Patent holdings for IPC class C07D 231/18
Total number of patents in this class: 315
10-year publication summary
18
|
23
|
17
|
38
|
27
|
21
|
11
|
11
|
13
|
10
|
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
Owner |
All patents
|
This class
|
---|---|---|
Inflazome Limited | 85 |
24 |
Theravance Biopharma R&D IP, LLC | 456 |
14 |
Bristol-myers Squibb Company | 4880 |
8 |
The Provost, Fellows, Foundation Scholars, and The Other Members of Board, of The College of The Holy and Undivided Trinity of Queen Elizabeth, Near Dublin | 165 |
8 |
The University of Queensland | 661 |
8 |
Novartis AG | 10744 |
7 |
Arena Pharmaceuticals, Inc. | 365 |
7 |
BASF SE | 20940 |
6 |
Northwestern University | 3398 |
6 |
Cardioxyl Pharmaceuticals, Inc. | 49 |
6 |
VALO Health, Inc. | 172 |
6 |
Bayer Pharma AG | 1053 |
5 |
The Johns Hopkins University | 5675 |
5 |
Nippon Soda Co., Ltd. | 895 |
5 |
Abbott Laboratories | 2402 |
4 |
Bayer AG | 3325 |
4 |
Takeda Pharmaceutical Company Limited | 2708 |
4 |
Merial, Inc. | 220 |
4 |
Nissan Chemical Corporation | 2033 |
4 |
Sumitomo Pharma Co., Ltd. | 605 |
4 |
Other owners | 176 |